Dr Liezl Gibhard
Dr Liezl Gibhard is a research professional with experience in biochemistry across platforms in research, development and scientific analysis.
She received her BSc (Hons.) and MSc degrees from the North-West University. She then continued with her PhD in Pharmaceutics at the same institution, carried out in the fields of malaria and nanomedicines. After completion of her studies, Liezl took up a post-doctoral position in the Division of Clinical Pharmacology at the University of Cape Town. Liezl received an NRF Innovation Fellowship to evaluate the pharmacokinetic and pharmacodynamic properties of novel antimalarial compounds administered alone and in dual combinations with artemisinins and derivatives thereof in in rodent models. Liezl joined the DMPK team at H3D on a permanent basis in mid-2015.
As H3D expanded her role expanded to establish and validate the NSG mouse model for malaria. This model is used to correlate pharmacokinetics with pharmacodynamic readouts and optimization of dosing regimens for novel antimalarial compounds.